Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas Tambe

Biocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management drug. Biocon aims to become a global medicines company driven by innovation. Insulin remains a strategic anchor. Oncology and immunology are key pillars. New areas like ophthalmology are being explored. Investments will target technology and AI.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rUT1ZgG
via IFTTT